ArticleEBioMedicine2025
Characterisation of phosphate transport in epididymis and prostate with possible relevance for semen quality.
Article in EBioMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Osteoprotegerin is strongly associated with calcium and magnesium in seminal fluid but not affected by denosumab.Journal of endocrinological investigation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSeminal phosphate concentrations are markedly higher than serum levels, suggesting a yet uncharacterised role of phosphate transporters in the male reproductive tract.
methodsAnalysis of type II and III phosphate co-transporter (SLC34A1-3/NPT2a-c, SLC20A1-2/PIT1-2) expression was conducted in prostate, seminal vesicle, and epididymis from wildtype mice fed normal or high-phosphate diet, mice treated with a NPT2a-inhibitor, Global Fgf23 knockout mice, and in human tissues. Seminal phosphate concentrations and semen quality were examined in 301 healthy men.
findingsPhosphate transporters are expressed in a zone-specific manner in the mouse epididymis and prostate. Elevated serum phosphate increased the expression of Slc34a1 (466 ± 24 vs. 1 ± 0.3, p < 0.05), Slc34a2 (54 ± 26 vs. 1 ± 0.2, p < 0.05), Slc34a3 (5 ± 0.3 vs. 1 ± 0.8, p < 0.001) and Slc20a1 (37 ± 18 vs. 1 ± 0.3, p < 0.05) to maintain a stable epididymal phosphate concentration. In contrast, prostatic phosphate concentrations increased (6.0 ± 0.4 vs. 4.5 ± 0.4, p < 0.05) with no change in expression of phosphate transporters except for lower Slc34a3 (0.1 ± 0.04 vs. 1 ± 0.4, p < 0.05). Hyperphosphatemic Fgf23 knockout mice had higher Slc20a2 expression (5.1 ± 1.1 vs. 1 ± 0.4, p < 0.05), while inhibition of NPT2a reduced phosphate concentrations specifically in caput epididymis (15 ± 0.1 vs. 19 ± 0.7, p < 0.001). Human epididymis, prostate and seminal vesicle showed distinct region-specific expression of phosphate-transporters with an abundant SLC34A2 expression in seminal vesicle. In healthy men, high seminal phosphate was positively linked with sperm concentration, motile sperm count, morphologically normal sperm (all, p < 0.05) and serum testosterone (p < 0.01).
interpretationThis study shows distinct expression and regulation of phosphate transporters in the epididymis, prostate and seminal vesicle. Moreover, both systemic and local phosphate concentrations may be of importance for reproductive organ function and semen quality.
fundingThis study was supported by funding from the Novo Nordisk Foundation, Denmark; Independent Research Fund Denmark, Denmark; Cleveland Foundation, UK; Beckett-Fonden, Denmark; Brødrene Hartmanns Fond, Denmark; Innovation Fund Denmark, Denmark.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.